Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Zoetis Inc. (ZTS:NYSE), powered by AI.
Zoetis Inc. is currently trading at $79.33. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Zoetis Inc. on Alpha Lenz.
Zoetis Inc.'s P/E ratio is 13.2.
“Zoetis Inc. trades at a P/E of 13.2 (undervalued) with strong ROE of 66.0%. Operating margin of 38.0% indicates strong profitability.”
Ask for details →Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
“Zoetis Inc. trades at a P/E of 13.2 (undervalued) with strong ROE of 66.0%. Operating margin of 38.0% indicates strong profitability.”
Ask for details →Zoetis Inc. (ticker: ZTS) is a company listed on NYSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 13,800 employees. Market cap is $35.2B.
The current price is $79.33 with a P/E ratio of 13.16x and P/B of 10.56x.
ROE is 65.99% and operating margin is 38.00%. Annual revenue is $9.5B.